HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM)

CUSIP: 40434H104

Q2 2017 13F Holders as of 30 Jun 2017

Type / Class
Equity / COM
Total 13F shares
2,479,115
Share change
-504,005
Total reported value
$6,593,310
Price per share
$2.66
Number of holders
17
Value change
-$1,754,422
Number of buys
8
Number of sells
10

Quarterly Holders Quick Answers

What is CUSIP 40434H104?
CUSIP 40434H104 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) as of Q2 2017

As of 30 Jun 2017, HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) was held by 17 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,479,115 shares. The largest 10 holders included Novo Holdings A/S, FMR LLC, Cormorant Asset Management, LLC, VANGUARD GROUP INC, GRANAHAN INVESTMENT MANAGEMENT INC/MA, PUTNAM INVESTMENTS LLC, Virtu KCG Holdings LLC, Bank of New York Mellon Corp, GEODE CAPITAL MANAGEMENT, LLC, and BlackRock Inc.. This page lists 17 institutional shareholders reporting positions in this security for the Q2 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.